The global Gene and Cell Therapies Targeting Cns Disorders Market is estimated to be valued at US$ 8.2 Bn in 2023 and is expected to exhibit a CAGR of 30% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Gene and cell therapies are emerging as promising treatments for various central nervous system (CNS) disorders by replacing or repairing damaged or mutated genes. They deliver therapeutic genes or cells directly into the central nervous system to halt or reverse the progression of diseases like Parkinson’s disease, Alzheimer’s disease, spinal cord injuries, and more.
Market key trends:
One of the major trends in the gene and cell therapies targeting CNS disorders market is the rising focus on developing gene therapies for neurological disorders with high unmet needs. For instance, devastating and currently untreatable disorders like Huntington’s disease, ALS, and multiple sclerosis are attracting significant investments from companies and research institutes for developing novel gene and cell therapy solutions. Furthermore, advanced delivery technologies like viral vectors are enabling efficient delivery of therapeutic genes across the blood-brain-barrier, driving development of therapies for genetic CNS disorders. Improved understanding of disease biology through multi-omics approaches is also supporting development of personalized and precision gene and cell therapies targeting specific disease subtypes and mutations.
SWOT Analysis
Strength: Gene and cell therapies targeting CNS disorders have high clinical potential and offer better treatment outcomes than conventional therapies. They directly target the root cause of disorders at a genetic level.
Weakness: These therapies have high development costs and risks associated with product failure in late stage clinical trials. Large scale manufacturing is also a challenge.
Opportunity: Increasing prevalence of CNS disorders such as Alzheimer’s, Parkinson’s, cerebral palsy offers huge market potential. Growing research and development activities also provide opportunities.
Threats: Stringent regulatory norms and long approval timelines pose threats. Reimbursement issues also restrict market growth.
Key Takeaways
The Global Gene And Cell Therapies Targeting Cns Disorders Market Size is expected to witness high growth, exhibiting CAGR of 30% over the forecast period, due to increasing R&D investments from pharmaceutical companies and venture capital firms.
Regional analysis: North America dominated the market and is expected to maintain its lead position during the forecast period. This is attributed to presence of advanced research infrastructure and funding in the region. However, Asia Pacific is anticipated to be the fastest growing regional market due to rising healthcare spending, low-cost clinical trials and expanding research facilities.
Key players operating in the gene and cell therapies targeting CNS disorders market are Novartis, Brainstorm Cell Therapeutics, Helminth, Core stem, Q therapeutics, Helminth, Rapa Therapeutics, Brainstorm Cell Therapeutics, Neuroblast, Osteocyte, Ferrer International, Neuralstem, Ferrer International, Semeia Cell Technologies, Labella Gene Therapeutics, Sangamon Therapeutics, Hoffmann-La Roche, Longeron, Soi Gene Therapies, Prevail Therapeutics (Eli Lilly and Company), Aerogeneration, Brain Neurotherapy Bio (Ask Bio), Unique Biopharma, Neurogenic Inc., Passage Bio, AXOVANT SCIENCES GMBH, Meira Tx Limited, Asclepios Biopharmaceutical (Ask Bio), Biogen, Sarepta Therapeutics, REGENXBIO Inc., Lysogen, Voyager Therapeutics, PTC Therapeutics.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
